Search Results - "BLASZKOWSKY, Lawrence"
-
1
Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma
Published in Annals of surgical oncology (01-04-2023)“…Background A multimodal approach of surgery and chemotherapy, with or without radiation, is the mainstay of therapy with curative-intent for resectable…”
Get full text
Journal Article -
2
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX
Published in Annals of surgery (01-04-2019)“…OBJECTIVE:The aim of this study was to determine (1) whether preoperative factors can predict resectability of borderline resectable (BR) and locally advanced…”
Get full text
Journal Article -
3
ASO Visual Abstract: Disparities in Receipt of Adjuvant Therapy after Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma
Published in Annals of surgical oncology (01-04-2023)Get full text
Journal Article -
4
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Published in Cancer discovery (01-02-2016)“…How genomic heterogeneity associated with acquired resistance to targeted agents affects response to subsequent therapy is unknown. We studied EGFR blockade in…”
Get more information
Journal Article -
5
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer
Published in Annals of surgery (01-01-2015)“…On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC…”
Get full text
Journal Article -
6
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Published in Nature medicine (01-09-2019)“…During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique resistance mechanisms in an individual patient…”
Get full text
Journal Article -
7
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Published in Clinical cancer research (15-10-2021)“…Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will…”
Get full text
Journal Article -
8
Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy
Published in Annals of surgery (01-05-2023)“…To identify disparities in access to NAT for PDAC at the prehospital and intrahospital phases of care. Delivery of NAT in PDAC is susceptible to disparities in…”
Get full text
Journal Article -
9
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Published in Journal of clinical oncology (10-02-2016)“…To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma…”
Get full text
Journal Article -
10
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
Published in PloS one (07-04-2022)“…Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments…”
Get full text
Journal Article -
11
Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Published in Clinical cancer research (15-04-2020)“…ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in real-time. We explored whether the quantitative percent change in ctDNA early…”
Get full text
Journal Article -
12
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial
Published in JAMA oncology (01-07-2018)“…Patients with borderline-resectable pancreatic ductal adenocarcinoma have historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation…”
Get more information
Journal Article -
13
Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Published in Annals of surgery (01-04-2013)“…Patients who undergo an R0 resection of their pancreatic ductal adenocarcinoma (PDAC) have an improved survival compared with patients who undergo an R1…”
Get full text
Journal Article -
14
Refusal of surgery for colon cancer: Sociodemographic disparities and survival implications among US patients with resectable disease
Published in The American journal of surgery (01-01-2021)“…We aimed to identify factors associated with refusal of surgery among patients with colon cancer. This 2004–2016 NCDB retrospective study identified AJCC stage…”
Get full text
Journal Article -
15
FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
Published in The oncologist (Dayton, Ohio) (01-05-2013)“…The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression‐free survival, and…”
Get full text
Journal Article -
16
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Published in Journal of clinical oncology (20-06-2009)“…To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response. We…”
Get full text
Journal Article -
17
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial
Published in JAMA oncology (01-07-2019)“…Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant approach is warranted. To evaluate the…”
Get more information
Journal Article -
18
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
Published in Journal of clinical oncology (20-08-2012)“…Both tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor and bevacizumab, a monoclonal antibody targeting VEGF, have…”
Get full text
Journal Article -
19
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
Published in Cancer (15-11-2011)“…BACKGROUND: The phosphoinositide 3‐kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma…”
Get full text
Journal Article -
20
Dose-Painted Intensity-Modulated Radiation Therapy for Anal Cancer: A Multi-Institutional Report of Acute Toxicity and Response to Therapy
Published in International journal of radiation oncology, biology, physics (2012)“…Purpose Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity. We report our multi-institutional…”
Get full text
Journal Article